4.6 Review

The Emerging Role of Major Regulatory RNAs in Cancer Control

期刊

FRONTIERS IN ONCOLOGY
卷 9, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2019.00920

关键词

long non-coding RNA; microRNA; biomarker; therapeutics; cancer

类别

资金

  1. National Natural Science Foundation of China [81972789]
  2. National Science and Technology Major Project [2018ZX10302205-004-002]
  3. Natural Science Foundation of Jiangsu Province [BK20161130]
  4. Six Talent Peaks Project in Jiangsu Province [SWYY-128]
  5. Technology Development Funding of Wuxi [WX18IVJN017]
  6. Major Project of Science and Technology in Henan Province [161100311400]
  7. Research Funds for the Medical School of Jiangnan University ESI Special Cultivation Project [1286010241170320]

向作者/读者索取更多资源

Alterations and personal variations of RNA interactions have been mechanistically coupled with disease etiology and phenotypical variations. RNA biomarkers, RNA mimics, and RNA antagonists have been developed for diagnostic, prognostic, and therapeutic uses. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are two major types of RNA molecules with regulatory roles, deregulation of which has been implicated in the initiation and progression of many human malignancies. Accumulating evidence indicated the clinical roles of regulatory RNAs in cancer control, stimulating a surge in exploring the functionalities of regulatory RNAs for improved understanding on disease pathogenesis and management. In this review, we highlight the critical roles of lncRNAs and miRNAs played in tumorigenesis, scrutinize their potential functionalities as diagnostic/prognostic biomarkers and/or therapeutic targets in clinics, outline opportunities that ncRNAs may bring to complement current clinical practice for improved cancer management and identify challenges faced by translating frontier knowledge on non-coding RNAs (ncRNAs) to bedside clinics as well as possible solutions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据